Design paper: The CapOpus trial: a randomized, parallel-group, observer-blinded clinical trial of specialized addiction treatment versus treatment as usual for young patients with cannabis abuse and psychosis.
Design paper: The CapOpus trial: a randomized, parallel-group, observer-blinded clinical trial of specialized addiction treatment versus treatment as usual for young patients with cannabis abuse and psychosis.
复制标题
DOI：
10.1186/1745-6215-9-42
复制
发表时间：
2008-07-11
期刊：
影响因子：
2.5
通讯作者：
Nordentoft M
中科院分区：
文献类型：
--
作者：
Hjorthøj C;Fohlmann A;Larsen AM;Madsen MT;Vesterager L;Gluud C;Arendt MC;Nordentoft M
一些研究表明，大麻使用和精神病之间的联系，以及在那些现有的精神病患者中更严重的精神病。目前没有足够的证据来决定治疗精神病患者滥用大麻的最佳方法。CapOpus试验的主要目的是评估一个专门的成瘾治疗计划对大麻滥用的额外影响，该计划在治疗中增加了小组治疗和动机访谈。本试验设计为随机、平行组、双盲临床试验。患者主要通过早期精神病检测团队，社区精神卫生中心和自信的社区治疗团队招募。患者被随机分配到两个治疗组中的一个，均持续六个月：1）专业成瘾治疗加常规治疗或2）常规治疗。专门的成瘾治疗是手工制作的，包括个人和基于团体的动机访谈和认知行为治疗，并包括患者的家庭和案例管理者。主要结果指标将是大麻消费量随时间的变化。其他结果指标包括精神病症状、认知功能、生活质量、社会功能和成本效益分析。ClinicalTrials.gov NCT 00484302。
A number of studies indicate a link between cannabis-use and psychosis as well as more severe psychosis in those with existing psychotic disorders. There is currently insufficient evidence to decide the optimal way to treat cannabis abuse among patients with psychosis. The major objective for the CapOpus trial is to evaluate the additional effect on cannabis abuse of a specialized addiction treatment program adding group treatment and motivational interviewing to treatment as usual. The trial is designed as a randomized, parallel-group, observer-blinded clinical trial. Patients are primarily recruited through early-psychosis detection teams, community mental health centers, and assertive community treatment teams. Patients are randomized to one of two treatment arms, both lasting six months: 1) specialized addiction treatment plus treatment as usual or 2) treatment as usual. The specialized addiction treatment is manualized and consists of both individual and group-based motivational interviewing and cognitive behavioral therapy, and incorporates both the family and the case manager of the patient. The primary outcome measure will be changes in amount of cannabis consumption over time. Other outcome measures will be psychosis symptoms, cognitive functioning, quality of life, social functioning, and cost-benefit analyses. ClinicalTrials.gov NCT00484302.
登录
查看更多内容
影响因子：
17.7
作者：
Barrowclough, C;Haddock, G;McGovern, J
通讯作者：
McGovern, J
影响因子：
14.8
作者：
Bowie, Christopher R.;Harvey, Philip D.
通讯作者：
Harvey, Philip D.
影响因子：
3.3
作者：
Brooks, R
通讯作者：
Brooks, R
DOI：
10.1007/s004060050064
发表时间：
1999-02-01
影响因子：
4.7
作者：
Caspari, D
通讯作者：
Caspari, D
影响因子：
--
作者：
Arseneault, L;Cannon, M;Moffitt, TE
通讯作者：
Moffitt, TE